Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 42 | 2024 | 185 | 6.650 |
Why?
|
| Hydroxyurea | 7 | 2015 | 34 | 1.210 |
Why?
|
| Antisickling Agents | 6 | 2015 | 14 | 1.170 |
Why?
|
| Hypertension, Pulmonary | 11 | 2017 | 78 | 1.150 |
Why?
|
| Pain | 6 | 2023 | 283 | 0.960 |
Why?
|
| Fetal Hemoglobin | 5 | 2017 | 13 | 0.880 |
Why?
|
| Vascular Diseases | 3 | 2014 | 33 | 0.820 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2014 | 727 | 0.600 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2014 | 860 | 0.580 |
Why?
|
| Pain Threshold | 1 | 2017 | 34 | 0.540 |
Why?
|
| Haplotypes | 4 | 2014 | 197 | 0.540 |
Why?
|
| Adult | 32 | 2024 | 13458 | 0.490 |
Why?
|
| Cardiovascular Diseases | 2 | 2013 | 729 | 0.490 |
Why?
|
| Humans | 53 | 2024 | 42163 | 0.460 |
Why?
|
| Hemolysis | 6 | 2014 | 59 | 0.450 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 188 | 0.440 |
Why?
|
| GTP Cyclohydrolase | 1 | 2014 | 4 | 0.430 |
Why?
|
| Mutation | 5 | 2013 | 1169 | 0.420 |
Why?
|
| Lipoproteins | 2 | 2013 | 68 | 0.400 |
Why?
|
| Male | 30 | 2024 | 22779 | 0.390 |
Why?
|
| Female | 31 | 2024 | 24018 | 0.390 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2013 | 40 | 0.380 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 36 | 0.360 |
Why?
|
| Rhabdomyosarcoma | 1 | 2009 | 1 | 0.320 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2009 | 2 | 0.320 |
Why?
|
| Hematologic Diseases | 1 | 2009 | 13 | 0.320 |
Why?
|
| Polymorphism, Genetic | 2 | 2008 | 200 | 0.310 |
Why?
|
| Middle Aged | 18 | 2024 | 11819 | 0.300 |
Why?
|
| Hemoglobins | 2 | 2011 | 112 | 0.290 |
Why?
|
| Genetic Markers | 3 | 2014 | 146 | 0.280 |
Why?
|
| Stroke | 2 | 2002 | 348 | 0.280 |
Why?
|
| Proportional Hazards Models | 5 | 2015 | 512 | 0.260 |
Why?
|
| Depression | 1 | 2014 | 837 | 0.260 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2007 | 31 | 0.260 |
Why?
|
| Adolescent | 14 | 2021 | 5950 | 0.250 |
Why?
|
| Alleles | 4 | 2014 | 352 | 0.250 |
Why?
|
| Anemia, Aplastic | 2 | 2016 | 2 | 0.240 |
Why?
|
| Young Adult | 10 | 2021 | 4936 | 0.240 |
Why?
|
| Tricuspid Valve Insufficiency | 4 | 2020 | 12 | 0.230 |
Why?
|
| Genetic Variation | 3 | 2014 | 429 | 0.220 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2016 | 181 | 0.220 |
Why?
|
| Proteinuria | 1 | 2024 | 55 | 0.210 |
Why?
|
| Iron | 3 | 2014 | 247 | 0.210 |
Why?
|
| Mannose-Binding Lectin | 2 | 2005 | 6 | 0.210 |
Why?
|
| Pyrazoles | 1 | 2024 | 93 | 0.210 |
Why?
|
| Cohort Studies | 6 | 2014 | 1729 | 0.200 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2023 | 10 | 0.200 |
Why?
|
| alpha-Thalassemia | 3 | 2014 | 4 | 0.200 |
Why?
|
| Hemoglobinopathies | 1 | 2023 | 5 | 0.200 |
Why?
|
| Prospective Studies | 6 | 2020 | 1574 | 0.200 |
Why?
|
| Receptors, IgG | 2 | 2005 | 53 | 0.200 |
Why?
|
| Prevalence | 3 | 2018 | 1597 | 0.200 |
Why?
|
| Pyrimidines | 1 | 2024 | 130 | 0.200 |
Why?
|
| Volatile Organic Compounds | 1 | 2023 | 20 | 0.200 |
Why?
|
| Thrombophilia | 1 | 2002 | 5 | 0.190 |
Why?
|
| Case-Control Studies | 5 | 2021 | 1266 | 0.190 |
Why?
|
| Risk Factors | 8 | 2014 | 3942 | 0.180 |
Why?
|
| Sickle Cell Trait | 1 | 2021 | 19 | 0.180 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 117 | 0.180 |
Why?
|
| Aged | 9 | 2021 | 7982 | 0.180 |
Why?
|
| Treatment Outcome | 5 | 2024 | 1586 | 0.180 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2021 | 19 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 5 | 2014 | 534 | 0.170 |
Why?
|
| Hypertension | 2 | 2024 | 823 | 0.170 |
Why?
|
| Gene Frequency | 3 | 2014 | 203 | 0.170 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 1066 | 0.170 |
Why?
|
| Ferritins | 3 | 2020 | 63 | 0.170 |
Why?
|
| Child | 9 | 2023 | 3381 | 0.170 |
Why?
|
| Orosomucoid | 1 | 2020 | 12 | 0.160 |
Why?
|
| Leg Ulcer | 2 | 2011 | 8 | 0.160 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 683 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 255 | 0.160 |
Why?
|
| Thalassemia | 2 | 2009 | 3 | 0.150 |
Why?
|
| Hospitals, Special | 1 | 2018 | 3 | 0.150 |
Why?
|
| Congo | 1 | 2018 | 3 | 0.150 |
Why?
|
| Patient Care | 1 | 2018 | 31 | 0.150 |
Why?
|
| United States | 7 | 2020 | 5072 | 0.140 |
Why?
|
| Bacteria | 1 | 2021 | 285 | 0.140 |
Why?
|
| Phenotype | 2 | 2014 | 774 | 0.140 |
Why?
|
| Survival Rate | 4 | 2020 | 353 | 0.140 |
Why?
|
| Touch | 1 | 2017 | 19 | 0.140 |
Why?
|
| Biomedical Research | 2 | 2013 | 467 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2014 | 587 | 0.140 |
Why?
|
| Hyperalgesia | 1 | 2017 | 23 | 0.140 |
Why?
|
| Cold Temperature | 1 | 2017 | 41 | 0.140 |
Why?
|
| Echocardiography | 3 | 2017 | 167 | 0.130 |
Why?
|
| Hematopoiesis | 2 | 2014 | 28 | 0.130 |
Why?
|
| Erythroid Cells | 2 | 2014 | 8 | 0.130 |
Why?
|
| Epoprostenol | 1 | 2017 | 28 | 0.130 |
Why?
|
| Hot Temperature | 1 | 2017 | 141 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2016 | 276 | 0.130 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2016 | 1 | 0.120 |
Why?
|
| Cholesterol, HDL | 2 | 2013 | 99 | 0.120 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 11 | 0.120 |
Why?
|
| Hematocrit | 2 | 2013 | 25 | 0.120 |
Why?
|
| Immunologic Memory | 1 | 2016 | 41 | 0.120 |
Why?
|
| HIV-1 | 1 | 2021 | 747 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 427 | 0.120 |
Why?
|
| Pregnancy Proteins | 1 | 2014 | 5 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 25 | 0.110 |
Why?
|
| Biological Clocks | 1 | 2014 | 52 | 0.110 |
Why?
|
| Plethysmography | 1 | 2014 | 6 | 0.110 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 285 | 0.110 |
Why?
|
| Endothelium | 1 | 2014 | 28 | 0.110 |
Why?
|
| Leukemia | 2 | 2005 | 54 | 0.110 |
Why?
|
| Heme | 1 | 2014 | 72 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 1051 | 0.100 |
Why?
|
| Logistic Models | 2 | 2013 | 1001 | 0.100 |
Why?
|
| Candidiasis | 2 | 2005 | 86 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 118 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 280 | 0.100 |
Why?
|
| Base Sequence | 2 | 2013 | 997 | 0.100 |
Why?
|
| Double-Blind Method | 2 | 2024 | 305 | 0.100 |
Why?
|
| Genotype | 3 | 2012 | 796 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2012 | 52 | 0.100 |
Why?
|
| Cation Transport Proteins | 1 | 2012 | 34 | 0.100 |
Why?
|
| Sleep | 1 | 2014 | 179 | 0.100 |
Why?
|
| Suicide | 1 | 2014 | 139 | 0.100 |
Why?
|
| Genome, Human | 1 | 2013 | 143 | 0.090 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2011 | 64 | 0.090 |
Why?
|
| Cell Differentiation | 2 | 2014 | 633 | 0.090 |
Why?
|
| Comorbidity | 1 | 2014 | 725 | 0.090 |
Why?
|
| Homozygote | 3 | 2011 | 77 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 2 | 2011 | 508 | 0.090 |
Why?
|
| Exercise Tolerance | 1 | 2011 | 22 | 0.090 |
Why?
|
| Hospitalization | 1 | 2015 | 482 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2011 | 47 | 0.090 |
Why?
|
| Alternative Splicing | 1 | 2011 | 92 | 0.090 |
Why?
|
| Cell Lineage | 1 | 2011 | 104 | 0.090 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2008 | 106 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 708 | 0.080 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 96 | 0.080 |
Why?
|
| Sex Factors | 1 | 2014 | 1008 | 0.080 |
Why?
|
| DNA | 1 | 2013 | 594 | 0.080 |
Why?
|
| Cell Line, Transformed | 1 | 2009 | 96 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 98 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2015 | 501 | 0.080 |
Why?
|
| Quality of Life | 1 | 2014 | 599 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 577 | 0.080 |
Why?
|
| Kidney Diseases | 2 | 2008 | 170 | 0.080 |
Why?
|
| Retrospective Studies | 1 | 2015 | 2485 | 0.070 |
Why?
|
| STAT3 Transcription Factor | 1 | 2009 | 97 | 0.070 |
Why?
|
| DNA Replication | 1 | 2009 | 153 | 0.070 |
Why?
|
| Inflammation | 2 | 2014 | 729 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 233 | 0.070 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2008 | 8 | 0.070 |
Why?
|
| Lipids | 1 | 2010 | 256 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2008 | 14 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2008 | 27 | 0.070 |
Why?
|
| Cell Cycle | 1 | 2009 | 348 | 0.070 |
Why?
|
| Arginine | 1 | 2008 | 75 | 0.070 |
Why?
|
| Mice | 3 | 2021 | 6490 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 1 | 2008 | 134 | 0.070 |
Why?
|
| HIV Infections | 1 | 2021 | 2535 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2008 | 132 | 0.070 |
Why?
|
| Age Distribution | 1 | 2008 | 249 | 0.070 |
Why?
|
| Brain | 1 | 2015 | 1452 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2008 | 362 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2021 | 246 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2009 | 381 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2015 | 733 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2009 | 973 | 0.060 |
Why?
|
| Erythropoietin | 1 | 2006 | 36 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 246 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2020 | 1516 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 3077 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2009 | 875 | 0.060 |
Why?
|
| Animals | 4 | 2021 | 16695 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 458 | 0.060 |
Why?
|
| Leukocyte Count | 2 | 2020 | 68 | 0.060 |
Why?
|
| Organic Anion Transporters, Sodium-Dependent | 1 | 2004 | 1 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 244 | 0.060 |
Why?
|
| Symporters | 1 | 2004 | 15 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2005 | 168 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 479 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 532 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 1554 | 0.050 |
Why?
|
| Genomics | 2 | 2004 | 289 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 711 | 0.050 |
Why?
|
| Disease Progression | 2 | 2021 | 661 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1420 | 0.050 |
Why?
|
| Iron Overload | 2 | 2014 | 10 | 0.050 |
Why?
|
| E-Selectin | 1 | 2023 | 23 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2003 | 75 | 0.050 |
Why?
|
| Jamaica | 1 | 2002 | 11 | 0.050 |
Why?
|
| Codon | 1 | 2002 | 40 | 0.050 |
Why?
|
| Open Reading Frames | 1 | 2002 | 81 | 0.050 |
Why?
|
| Introns | 1 | 2002 | 80 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 2598 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 135 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2002 | 195 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2017 | 662 | 0.050 |
Why?
|
| Kringles | 1 | 2021 | 5 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2021 | 69 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 144 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2011 | 206 | 0.040 |
Why?
|
| Phylogeny | 1 | 2004 | 740 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 245 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 116 | 0.040 |
Why?
|
| Models, Genetic | 2 | 2014 | 181 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 1848 | 0.040 |
Why?
|
| Neutrophils | 1 | 2020 | 141 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2023 | 2111 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 850 | 0.040 |
Why?
|
| Acute Disease | 2 | 2011 | 156 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2014 | 1265 | 0.040 |
Why?
|
| Age Factors | 2 | 2011 | 1139 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2017 | 101 | 0.030 |
Why?
|
| Uveitis | 1 | 2016 | 5 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 47 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 61 | 0.030 |
Why?
|
| Rest | 1 | 2015 | 33 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 64 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2016 | 90 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 91 | 0.030 |
Why?
|
| Recurrence | 1 | 2016 | 149 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2014 | 12 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2015 | 139 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2015 | 132 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2016 | 268 | 0.030 |
Why?
|
| Hemin | 1 | 2014 | 6 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2014 | 19 | 0.030 |
Why?
|
| K562 Cells | 1 | 2014 | 32 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 88 | 0.030 |
Why?
|
| alpha-Globins | 1 | 2014 | 4 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 200 | 0.030 |
Why?
|
| Creatinine | 1 | 2014 | 102 | 0.030 |
Why?
|
| Walking | 1 | 2014 | 85 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 7 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2014 | 168 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2013 | 41 | 0.020 |
Why?
|
| Mortality | 1 | 2014 | 174 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2012 | 30 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 41 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2014 | 301 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 431 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 19 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 293 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2011 | 33 | 0.020 |
Why?
|
| Hemoglobin, Sickle | 1 | 2011 | 11 | 0.020 |
Why?
|
| Exercise Test | 1 | 2011 | 75 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 87 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 249 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 91 | 0.020 |
Why?
|
| Uric Acid | 1 | 2011 | 29 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 1010 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 103 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2005 | 541 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 310 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 143 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 438 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 411 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 454 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 845 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 638 | 0.020 |
Why?
|
| Triglycerides | 1 | 2010 | 146 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 692 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 421 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 1416 | 0.020 |
Why?
|
| omega-N-Methylarginine | 1 | 2008 | 8 | 0.020 |
Why?
|
| Macrophages | 1 | 2012 | 515 | 0.020 |
Why?
|
| Cholesterol | 1 | 2010 | 230 | 0.020 |
Why?
|
| Citrulline | 1 | 2008 | 14 | 0.020 |
Why?
|
| Creatine | 1 | 2008 | 10 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 261 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 1058 | 0.020 |
Why?
|
| Mitogens | 1 | 2007 | 10 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 12 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2007 | 84 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 289 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 311 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 916 | 0.020 |
Why?
|
| Leukocytes | 1 | 2007 | 79 | 0.020 |
Why?
|
| Oxygen | 1 | 2008 | 217 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2007 | 80 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 233 | 0.020 |
Why?
|
| Gene Components | 1 | 2004 | 2 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2008 | 960 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 522 | 0.010 |
Why?
|
| Base Composition | 1 | 2004 | 25 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2004 | 62 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2004 | 85 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1559 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 599 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 279 | 0.010 |
Why?
|
| Candida | 1 | 2003 | 41 | 0.010 |
Why?
|